Renata PLC launches Cabergoline in France and Nordic Countries
Renata PLC has successfully launched its Cabergoline 0.5 tablets in France and the Nordics, marking its first entry into these key European markets. Manufactured at Renata's EU GMP-approved facility, Cabergoline is used to treat hyperprolactinemic disorders by lowering elevated prolactin levels and is also indicated for Parkinson's disease.
This launch builds on Renata's experience in the UK market and signals its continued expansion into highly regulated international markets. The product, also available in Bangladesh under the brand name Cabolin, underscores Renata's ambition to expand patient access to specialised medications worldwide, reinforcing its position as an emerging global pharmaceutical manufacturer.
Keep updated, follow The Business Standard's Google news channel
